LAUSR

The article presents the study results of the third-generation fluoroquinolone antibiotic danofloxacin efficacy and safeness in the treatment of pig colibacillosis. Susceptibility testing of Escherichia coli field strains isolated from the feces of piglets with acute intestinal infection to danofloxacin was carried out. A high level of E. coli isolates susceptibility to danofloxacin was established: the average diameter of the growth inhibitory zone around the antibiotic disc was 29.1±1.008 mm (n=20) and the average minimum inhibitory concentration (MIC) of danofloxacin for E. coli isolates was 0.28±0.054 µg/ml (n=20). The usage of therapeutic doses of the new danofloxacin-based antimicrobial drug Danoflox 2.5% (solution for injection) caused clinical recovery of piglets with colibacteriosis. During and after antibiotic therapy, no negative reactions or adverse events in animals were observed that indicates about a high level of the drug safeness when administered to pigs at the recommended dosage. The drug safeness and the absence of negative impact on the physiological and functional state of piglets with colibacteriosis were confirmed by the laboratory studies of hematological, immunological and biochemical blood parameters before and after antibiotic therapy. Before treatment in the blood of piglets an increase of hematocrit, erythrocyte and leukocyte count, erythrocyte sedimentation rate, and a high percentage of rod-shaped neutrophils were observed. After the treatment all indicators of the total blood analysis were within the physiological rate. Conducted antibiotic therapy contributed to the increase of phagocytic index and a considerable increase of serum lysozyme activity. After Danoflox 2.5% administration a rising of serum albumin and β-globulin percentage and normalization of the level of α- and γ-globulins in the proteinogram was observed. Other investigated serum biochemical parameters of animals were not over the acceptable physiological limits.